Myslenice

Researchers are investigating whether accelerated surgery for hip fracture patients with acute myocardial injury can reduce death rates within 90 days compared to the usual care. This international, multicenter, randomized controlled trial also evaluates secondary outcomes like walking ability, time to first mobilization, major complications including heart attacks and stroke, delirium, pain, length of hospital stay, and quality of life. The trial compares two approaches one group receives rapid medical clearance and surgery within 6 hours of meeting eligibility, while the other group undergoes hip fracture repair following standard hospital procedures. Surgery and care are performed according to institutional guidelines, with the accelerated group targeting quick operating room arrival. Participants will be monitored for 90 days after randomization. Researchers will assess survival, walking independence, major cardiovascular complications, delirium episodes, pain levels, and hospital discharge timing. This includes tracking events like myocardial infarction, heart failure, and stroke. The study aims to gather comprehensive data on safety and recovery outcomes related to timing of surgery in this patient group.

Researchers are evaluating the safety and effects of three different dose levels of NMD670 in adult patients with Myasthenia Gravis who have antibodies against AChR or MuSK. This Phase 2 study is designed to find the appropriate dose and understand how the drug compares to a placebo over 21 days of treatment. The study focuses on adults diagnosed with moderate to severe forms of Myasthenia Gravis. Participants will receive one of three doses of NMD670 or a placebo, taken as tablets twice a day for 21 days. The study randomly assigns participants to these groups and is conducted under a double-blind method so that neither participants nor researchers know which treatment is given. The trial evaluates the effects of NMD670 on muscle strength and daily living activities using several rating scales. During the study, participants will be monitored for changes in their muscle strength and symptoms using specific clinical scores from the start of treatment to day 21. Safety assessments will include physical exams, laboratory tests, vital signs, ECGs, and eye exams before and after treatment. Researchers will also track any side effects or serious events during the dosing period. Participation will last about three weeks with close medical follow-up to assess the study drugs impact.